Severe COVID-19 pneumonia – Page 21 – Communicable Diseases Research

Respiratory characteristics and related intraoperative ventilatory management for patients with COVID-19 pneumonia

Special Feature: Special Article

Published on 2020-08-312022-10-30
Journal: Journal of anesthesia [Category] COVID-19, MERS, SARS,

Tocilizumab and steroid treatment in patients with COVID-19 pneumonia

코로나19 폐렴 환자에서 토실리주맙과 스테로이드 치료

Research Article

Published on 2020-08-202022-08-13
Journal: PLoS ONE [Category] Biochemistry, COVID-19, MERS, SARS,

[키워드] 95%CI adjusted age analyses anti-inflammatory treatment Comorbidities Comorbidity controls coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pneumonia Cox regression analysis darunavir death defined determine difference early treatment Efficacy Endpoint endpoints Evidence failure group hazard hazard ratio Hospital admission Hydroxychloroquine immune response IMPROVE intravenously Intubated intubation IQR lead male median median age Methylprednisolone non-intubated patient non-intubated patients not intubated outcome overall survival PaO Patient patients with COVID-19 Pneumonia primary endpoint Propensity score Ratio Respiratory failure Result Ritonavir Severe COVID-19 pneumonia single-center study Standard of care steroid steroid treatment Steroids subcutaneously survival Tocilizumab treated patient Treatment treatment with tocilizumab with COVID-19
[DOI] 10.1371/journal.pone.0237831 PMC 바로가기 [Article Type] Research Article

Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System

Immunology

Published on 2020-08-142022-11-01
Journal: Frontiers in Immunology [Category] COVID-19, MERS, SARS,

[키워드] Activation Administered Admission age ambient C-reactive protein C1 esterase inhibitor Case series Chest Clinical improvement complement complement system Computed tomography Concentration Conestat alfa Contact contact activation system Controlled clinical trial COVID-19 declined dose dysregulated immune response Efficacy elevated Evidence hyperinflammation Immediate Inflammation inflammatory cascade Inflammatory marker intervals Intravenous injection Kallikrein-kinin system Level lung involvement majority mechanical ventilation median Nasopharyngeal swab occurred oxygen saturation oxygen supplementation Patient patients potential benefit preventing disease progression progressive disease regulator required Safe SARS-CoV-2 severe coronavirus disease severe COVID-19 severe COVID-19 patients Severe COVID-19 pneumonia Switzerland System treated Treatment University Hospital Basel
[DOI] 10.3389/fimmu.2020.02072 PMC 바로가기 [Article Type] Immunology

Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial

중증 또는 치명적인 COVID-19 폐렴의 치료를 위한 Auxora 대 표준 치료: 무작위 대조 시험의 결과

Research

Published on 2020-08-142022-08-13
Journal: Critical Care [Category] MERS, 임상,

[키워드] 95% CI Abstract Administered adverse event Auxora baseline blinded calcium Calcium release-activated calcium Calcium release-activated calcium channel inhibitors channel inhibitor conducted COVID-19 COVID-19 pneumonia CRAC CRAC channel inhibitor CRAC channel inhibitors Critical cytokine demonstrated died dose Efficacy Enrollment FDA Fewer patient Fewer patients Guidance intravenously Invasive mechanical ventilation mechanical ventilation median time nine novel Open-label open-label study design Ordinal Scale outcome PaO Patient patient population patients with COVID-19 placebo-controlled study Pneumonia Proinflammatory cytokine Proinflammatory response proportion Pulmonary endothelium randomization Randomized Randomized controlled trial rate ratio receive receiving Regulatory respiratory respiratory complication Respiratory complications Result resulting risk safety profile Serious Adverse Event Serious Adverse Events Severe COVID-19 pneumonia significantly Standard of care study enrollment the median Time to recovery Tolerability transition Treatment Trial registration Two patient two patients
[DOI] 10.1186/s13054-020-03220-x PMC 바로가기 [Article Type] Research

Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy

COVID-19 폐렴의 치료: 태반 유래 세포 요법의 사례

Article

Published on 2020-07-212022-09-10
Journal: Stem cell reviews and reports [Category] MERS, 임상, 치료제,

[키워드] acute respiratory distress acute respiratory distress syndrome administration AEC amniotic Anti-inflammatory Antiviral ARDS candidate Cell clinical evidence clinical trial clinical trials conditions COVID-19 COVID-19 disease COVID-19 pneumonia COVID19 pneumonia cytokine Cytokine storm Cytopathic effect death Efficiency elicited epithelial cell epithelial cells excessive immune response fatality fetal fetal membranes form Lung infection membranes MOST pharmacological agents Placenta Pneumonia reported respiratory distress responsible rising severe COVID-19 disease Severe COVID-19 pneumonia severe SARS severe SARS-CoV-2 stromal cell stromal cells syndrome the disease therapy Treatment virus
[DOI] 10.1007/s12015-020-10004-x PMC 바로가기 [Article Type] Article

Utility of D-dimer as a Prognostic Factor in SARS CoV2 Infection: A Review

Article

Published on 2020-07-212022-10-27
Journal: American journal of medical case reports [Category] COVID-19,

[키워드] abnormality acute respiratory distress anticoagulation ARDS benefit Case report clinical decision Coagulopathy Cohort studies Corona virus coronavirus disease-2019 COVID-19 COVID-19 infection COVID-19 patient Critically ill D-dimer D-dimer level death disease severity Disseminated intravascular coagulation Efficacy elevated event Evidence evidenced Factor help immune dysregulation implicated increased mortality manifestation microvascular thrombosis and macrovascular thrombosis Mortality non-survivor pandemic Patient pediatric Pneumonia Population predict progression public health emergency randomized control trial regimen review risk risk stratification Severe COVID-19 pneumonia severity of COVID-19 shown suggested Survivors syndrome therapeutic anticoagulation thromboembolic Thromboembolic events utility venous thromboembolic virus WHO World Health Organization
PMC 바로가기 [Article Type] Article

Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation

체외막 산소 공급이 필요한 중증 COVID-19 폐렴 환자의 사이토카인 흡착

Research Letter

Published on 2020-07-142022-08-13
Journal: Critical Care [Category] 임상,

[키워드] Adsorption extracorporeal membrane oxygenation Patient Severe COVID-19 pneumonia
[DOI] 10.1186/s13054-020-03130-y PMC 바로가기 [Article Type] Research Letter

Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia

Research Letter

Published on 2020-07-112022-11-01
Journal: Critical Care [Category] COVID-19,

[키워드] Patient Severe COVID-19 pneumonia stem cell umbilical
[DOI] 10.1186/s13054-020-03142-8 PMC 바로가기 [Article Type] Research Letter

Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol

Letter

Published on 2020-06-262022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 24 hour Administered airway allocation concealment Alpha ambient analysed aneurysms Anticoagulant treatment anticoagulation antiplatelet Arm arterial assigned Atrial fibrillation bleeding bleeding event block size Blood BMI Body Breastfeeding breath calculated Cancer clinical clinically Coagulopathy Concomitant conjunctival Continuous contributed Control control group Controlled trial corpus COVID-19 COVID19 criteria Critical D-dimer D-dimer level Day death defined detect diagnostic discharged disease severity dissemination dosage dose effective Efficacy and safety element enoxaparin Epistaxis EudraCT event events expected fibrinogen level gingival bleeding group Haemoglobin haemoptysis health-care hematemesis hematoma hemodynamic heparin High dose high risk history hospital discharge Hospital stay hospitalized patient hypersensitivity Hypothesis IL-6 Impaired impairing improvement IMV In-hospital indication initiated Inpatient INR internal Intervention intervention group Intra-articular intramuscular invasive Invasive mechanical ventilation involved Italian Italy laboratory parameter LMWH low dose low-molecular weight heparin macroscopic Major major bleeding management Mechanical mechanical ventilation medical intervention Medicine Modena NIV Non-invasive number objective occur Occurrence open label ophthalmic oral anticoagulant outcome oxygen paO2/fiO2 parallel group participant pathology Patient performed Pharyngeal swab plasma Platelet Pneumonia positive pregnancy test Presence pressure Primary outcome prophylactic dose prosthetic protocol random randomisation randomised randomised controlled randomised controlled trial randomization Rate receiving recorded recruited Rectal Bleeding reduce reduction in Registered renal function reported required respiratory risk risk of death Sample size SARS-CoV-2 secondary secure Severe COVID-19 pneumonia severe disease significantly Spontaneous standard oxygen therapy Stata status stratified stroke study drug Study protocol subcutaneously surgical susceptible symptomatic syndrome therapeutic dose therapy thrombocytopenia time transfusion Treatment unfractionated heparin unit Vascular venipuncture Venous Thromboembolism web-based system website weight Withdrawal worsening
[DOI] 10.1186/s13063-020-04475-z PMC 바로가기 [Article Type] Letter

Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-192022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 1:1 24 hour acute respiratory distress Administered administration Aerogen Aerogen Solo® Aerosols age airway alveolar alveolar injury anticipated ARDS backbone Berlin criteria blinded blocker Breastfeeding carrier cell-free DNA citrullinated histones clearance cleave Clinical practice clinical trial comparator Compound computer-generated consecutive patient control arm coronavirus 2 coronavirus disease COVID-19 COVID-19 patients criteria damage-associated molecular pattern DAMP DAMPs diagnosed with COVID-19 dissemination distal Dornase alfa dose double-stranded DSMB Efficacy element eliminated enteral nutrition Extracellular extracellular DNA fibrosis glycemic control hospital Hospitalized hospitals hyperinflammation hypersensitivity ICU Inclusion inclusion criteria induce Inflammation intensive care interim analysis Intervention Ireland less looser lung lung damage Lungs management mechanical ventilation mechanically ventilated patient monitoring board myeloperoxidase NET NETs neutrophil Neutrophil extracellular trap Neutrophil extracellular traps number objective Occurrence Open-label outcome PaO Paris participant Patient patients PEEP performed Pneumocytes Primary outcome progression Prone position Protective protocol randomisation randomised randomised controlled trial Randomized receive recruit recruitment reduce reducing Registered respiratory Roche Rothschild Sample size SARS-CoV-2 secretion Sedation Severe COVID-19 pneumonia severe pneumonia severity statistical analysis status study group Study protocol Switzerland syndrome to define Toxicity tracheal Treatment Trial usual care Ventilation vibrating mesh nebulizer Volume website
[DOI] 10.1186/s13063-020-04488-8 PMC 바로가기 [Article Type] Letter